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1  | ETIOLOGY AND DESCRIPTION OF 
PATHOGEN
Human T‐cell lymphotrophic virus 1 (HTLV)‐1 is an enveloped, sin‐
gle‐stranded RNA virus from the deltaretrovirus genus of the 
Retroviridae family. It was the first discovered human retrovirus and 
the only human pathogen within the oncovirus subfamily.1 Other 
viruses within this subfamily include HTLV‐2, bovine leukemia virus 
(BLV), simian T‐cell leukemia virus (STLV), HTLV‐3, and HTLV‐4. The 
significant homology between HTLV‐1 and STLV‐1 suggests trans‐
mission of the virus between species with ultimate emergence of a 
separate human pathogen. HTLV‐1 is considered to be the most on‐
cogenic of human pathogens given its direct carcinogenic effect with 
clonal viral integrations into the progenitor cells that develop into 
adult T‐cell leukemia/lymphoma (ALT).2 Although the overall rates 
of HTLV‐1 infection worldwide are low, carriers have a 5%‐10% risk 
of development of ATL over their lifetime, which is higher than the 
malignant potential associated with infection by other oncogenic vi‐
ruses such as human papillomavirus or human herpesvirus‐8. HTLV‐1 
carries a unique region different from other retroviruses which en‐
code for regulatory proteins important for viral pathogenesis. HTLV‐1 
establishes latent infection in lymphocytes and infection persists for 
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These updated guidelines from the Infectious Diseases Community of Practice of the 
American Society of Transplantation review the diagnosis, prevention, and manage‐
ment of Human T‐cell lymphotrophic virus 1 (HTLV)‐1 in the pre‐ and post‐trans‐
plant period. HTLV‐1 is an oncogenic human retrovirus rare in North America but 
endemic in the Caribbean and parts of Africa, South America, Asia, and Oceania. 
While most infected persons do not develop disease, <5% will develop adult T‐cell 
leukemia/lymphoma or neurological disease. No proven antiviral treatment for es‐
tablished HTLV‐1 infection is available. The effect of immunosuppression on the de‐
velopment of HTLV‐1‐associated disease in asymptomatically infected recipients is 
not well characterized, and HTLV‐1‐infected individuals should be counseled that im‐
munosuppression may increase the risk of developing HTLV‐1‐associated disease and 
they should be monitored post‐transplant for HTLV‐1‐associated disease. Currently 
approved screening assays do not distinguish between HTLV‐1 and HTLV‐2, and rou‐
tine screening of deceased donors without risk factors in low seroprevalence areas 
is likely to result in significant organ wastage and is not recommended. Targeted 
screening of donors with risk factors for HTLV‐1 infection and of living donors (as 
time is available to perform confirmatory tests) is reasonable.
K E Y W O R D S
complication: infectious, donors and donation: donor‐derived infections, infection and 
infectious agents, viral: human T‐lymphotropic virus
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life. Unlike HTLV‐1, the link between HTLV‐2 and human disease is 
uncertain, although there have been occasional case reports of neu‐
rological disease, inflammatory disorders, and leukemia in infected 
patients.3 Thus at present, for the purpose of organ donation, HTLV‐2 
is not considered a human pathogen and organs from HTLV‐2‐posi‐
tive donors are generally not considered to present an increased risk 
of donor‐derived disease compared to organs from HTLV‐2‐negative 
donors. This guideline focuses on HTLV‐1 infection.
2  | EPIDEMIOLOGY AND RISK FAC TORS
Human T‐cell lymphotrophic virus 1 is endemic in the Caribbean, 
parts of South America (highest rates reported in Brazil, 
Peru, Ecuador, and Venezuela), West Africa, Asia (particularly 
Southwestern Japan), and Oceania. In most areas of high endemicity, 
2%‐6% of adults are infected, although rates as high as 50% have re‐
cently been reported in some Australian aboriginal communities.4,5 
Infection is much less common in North America. For example, in 
the United States (US), 0.035%‐0.046% of blood donors are infected 
with HTLV‐1 or HTLV‐2.6 Among potential organ donors in France 
and the United States, similarly low rates of HTLV‐1 (0.03%‐0.067%) 
have been reported.7,8 Nonetheless, areas of focal higher seropreva‐
lence may exist in countries with very low overall rates of HTLV‐1.9 
In endemic areas, breastfeeding is the predominant mode of trans‐
mission,5 but transplacental transmission as well as transmission at 
the time of delivery also occur.10 HTLV‐1 may be transmitted via 
intravenous drug use, sexual intercourse (inefficiently), solid‐organ 
transplantation (SOT), and transfusion of cell‐containing blood prod‐
ucts (14.4%‐47.3% of recipients).11,12 HTLV‐2, in contrast, is primar‐
ily found in intravenous drug users and sexual contacts of infected 
persons and is endemic in some indigenous populations of North, 
Central, and South America, and in West and Central Africa.
3  | CLINIC AL MANIFESTATIONS
While most patients remain asymptomatic, following a pro‐
longed period of latency (typically years to decades) 2%‐5% of in‐
fected patients develop adult T‐cell leukemia/lymphoma (ATL). In 
Southwestern Japan, 75% of Non‐Hodgkins Lymphoma (NHL) is 
ATL.13 In addition to ATL, a small percentage of infected individu‐
als develop severe neurological disease termed HTLV‐1‐associ‐
ated myelopathy/tropical spastic paraparesis (HAM/TSP). Other 
inflammatory disorders (eg, Sjogren’s syndrome, uveitis, interstitial 
pneumonitis), and less severe neurological disease have also been 
associated with HTLV‐1. Children with vertically transmitted HTLV‐1 
may develop an infective dermatitis characterized by an exudative, 
eczematous rash early in life and complicated by bacterial superin‐
fection. Nearly half of these children may go on to develop HAM/
TSP.14 While some antiretroviral compounds demonstrate in vitro 
activity, no effective antiviral therapy has been demonstrated for 
established HTLV‐1 infection.
3.1 | Recipients positive pre‐transplantation
The effect of immunosuppression on the natural history of HTLV‐1 
is not well defined as very few cases have been described. This is 
an important issue in determining the safety of organ transplanta‐
tion in HTLV‐1‐positive recipients. Case series from Japan describe 
35 HTLV‐1‐positive kidney recipients with long‐term follow‐up; no 
HTLV‐1 disease occurred.15‐17 In contrast, a series of patients with 
post‐transplant lymphoproliferative disease (PTLD) describes the 
development of HTLV‐1‐associated ATL in five renal transplant re‐
cipients (unknown if all cases were infected pre‐transplant) with 
death occurring in 4/5 patients.18 Among 26 HTLV‐1‐positive living 
donor liver recipients, 4 (15%) developed ATL with fatal outcomes 
in all cases.19 Although there are only a limited number of published 
reports describing HTLV‐1‐associated outcomes in SOT recipients 
who were seropositive prior to transplantation, based on the exist‐
ing data overall survival does not seem to differ between HTLV‐1‐
positive and HTLV‐1‐negative recipients.
3.2 | Donor‐derived HTLV‐1 infection
From 1999 to 2009 (when the requirement to screen SOT recipients 
for HTLV‐1 in the US was eliminated), 162 HTLV 1/2 screen‐positive 
organs were transplanted in the United States with no HTLV‐1‐as‐
sociated disease described in recipients.8,20,21 In virtually all cases, 
however, confirmatory tests were not performed on donors and 
analysis based on the performance of the HTLV‐1/2 screening assay 
in a low seroprevalence population indicates that most of these do‐
nors had HTLV‐2 or a false‐positive screening assay.8 Further, the 
OPTN database tracks malignancy but not neurological outcome. 
Thus, the absence of reports of HTLV‐1‐associated disease in this 
population does not indicate that true‐positive HTLV‐1 organs can 
be safely transplanted.
Proven HTLV‐1 transmission from seropositive donors to se‐
ronegative recipients has historically been described without 
known development of disease.19‐24 Recently, however, cases of 
proven or probable donor to recipient transmission of HTLV‐1 
and resulting disease have been increasingly reported. In most 
cases, HTLV‐1‐associated HAM developed between 3 months 
and 4 years post‐transplantation.25‐30 Case reports have gener‐
ally been from areas with higher rates of HTLV‐1 infection, but at 
least one case occurred in the US and involved a donor from the 
Dominican Republic.29 A recent larger study of renal transplant 
recipients in Japan, an HTLV‐1 endemic region, demonstrated 
alarming findings upon retrospective review of transplant recip‐
ients years post‐transplantation.31 This study reported outcomes 
of 99 recipients out of 180 transplantations in which the donor, 
recipient, or both were known to be HTLV‐1‐positive at the time 
of transplant. Among recipients who were HTLV‐1‐negative and 
received their organ from an HTLV‐1‐positive donor, 87% were 
confirmed to have seroconversion post‐transplant and HAM de‐
veloped in 40%, demonstrating a substantially higher risk of dis‐
ease compared to recipients who were already HTLV‐1‐positive 
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prior to transplant. Similar to previous reports, the median time 
to development of HAM in this cohort was 3.8 years.31 This study 
emphasizes the need to consider donor screening when donors 
are from an HTLV‐1 endemic region, particularly when recipients 
are unlikely to be infected. While in some cases, rapid develop‐
ment of HAM has been observed post‐transplant, and it is diffi‐
cult to compare the anticipated time to development of disease 
from donor‐derived infection with that of natural infection in 
otherwise healthy individuals. Even less clear is the association 
between HTLV‐1‐positive donors and the development of ATL in 
seronegative recipients. Rare cases of ATL have been reported in 
SOT recipients, but in many cases the recipients themselves were 
HTLV‐1‐positive prior to transplantation and the malignant cells 
reflected recipient origin of HTLV‐1 infection.17,18 Given the pro‐
longed time to development of ATL among otherwise healthy in‐
dividuals who are HTLV‐1‐positive, and the very limited long‐term 
follow‐up data to evaluate such outcomes in SOT recipients, char‐
acterizing the risk of development of ATL in HTLV‐1‐negative SOT 
recipients with seropositive donor organs is challenging.
4  | DIAGNOSTIC STR ATEGIES
4.1 | Laboratory diagnosis of HTLV‐1
Enzyme‐linked immunosorbent assays (EIA) are currently used as 
screening tests for HTLV‐1/2. These tests do not distinguish be‐
tween HTLV‐1 and HTLV‐2. Further, diagnosis of HTLV‐1 infection 
is a two‐step process requiring a confirmatory assay. The most 
commonly used confirmatory assays include Western Blot and line 
immunoassays. Depending on the assay design and the results in 
a particular patient, these confirmatory immunoassays may dis‐
tinguish between HTLV‐1 and HTLV‐2. Polymerase chain reaction 
(PCR) tests may also be useful to confirm infection (particularly in 
the case of an indeterminate confirmatory test) and can distinguish 
between infection with HTLV‐1 and HTLV‐2. As plasma viremia is 
not prominent in HTLV‐1 infection, PCR tests are best performed on 
peripheral blood mononuclear cells (PBMCs). In some studies, how‐
ever, PCR is less sensitive than serological methods for the diagnosis 
of HTLV‐1/2, and may be even lower for HTLV‐2.32 Both Abbott and 
Avioq produce FDA‐approved HTLV‐1/2 screening tests that are in‐
dicated for screening of blood donors, organ donors, and for clinical 
diagnosis of HTLV infection; the MP Diagnostics HTLV Blot 2.4 is 
the only FDA‐approved confirmatory test with an indication for use 
as a supplemental, specific test to confirm repeatedly reactive re‐
sults by FDA‐approved screening tests in human serum and plasma 
samples. The HTLV Blot 2.4 test is not intended for use in medical 
diagnosis. In most settings, confirmatory results are not available in 
a time frame adequate to make decisions regarding deceased donor 
organ donation.
Screening EIA tests are highly sensitive but have poor positive 
predictive value when applied to a low seroprevalence population. 
For example, using the Abbott HTLV‐I/II EIA assay (now discontin‐
ued) 15 215 blood donors, 51 (0.35%) were repeatedly reactive; only 
10 of these had positive confirmatory tests and only 4 had confirmed 
HTLV‐1. Thus, only 4/51 (7.9%) of screen‐positive patients had con‐
firmed HTLV‐1 infection.33 In patients with medical conditions un‐
related to HTLV‐1/2, higher rates of positive screens are obtained 
(26/639), but only 3/26 were confirmed to have HTLV‐1 infection.33 
Likewise, among potential organ donors, HTLV‐1 infection could not 
be confirmed in the majority of screen‐positive donors.8
4.2 | Recommendations
• Whenever possible, HTLV‐1/2 screen‐positive results should be 
confirmed with western blot, line immunoassay, or polymerase 
chain reaction (strong, low).
5  | TRE ATMENT
Currently, no proven medical treatment for asymptomatic carri‐
ers of HTLV‐1 exists. Antiretroviral effective in HIV infection have 
achieved mixed results at best in reducing HTLV proviral loads (the 
typically stable amount of virus present in infected cells),34‐38 and 
this is unsurprising as viral replication is sustained by cellular division 
rather than highly active viral production.35 Other proposed treat‐
ments for asymptomatic carriers or patients with HAM/TSP include 
corticosteroids, alpha interferon, anti‐CD25 monoclonal antibody, 
cyclosporine, and valproic acid which increases viral expression 
theoretically leading to enhanced immune surveillance.35 Overall, 
treatment is focused on management of sequelae of HTLV‐1 infec‐
tion—namely ATL and HAM/TSP—in carriers who develop HTLV‐1‐
associated disease.
5.1 | Recommendations
• No specific proven treatment for asymptomatic HTLV‐1 infection 
is currently available (weak, very low).
6  | PRE VENTION
6.1 | Donor screening
As a result of both the planned discontinuation of the Abbott HTLV‐I/
II assay in 2009 and concern regarding the high false‐positive rate 
of available assays, an analysis of universal HTLV‐1 screening in de‐
ceased donors was undertaken. This suggested that 167‐227 unin‐
fected organs were discarded yearly due to false‐positive screening 
tests.8 A separate analysis estimated that in a low prevalence popu‐
lation the ratio of false‐positive to true‐positive HTLV‐1 screening 
assays was 40:1.39 Based on these considerations, the requirement 
for HTLV‐1 screening of deceased donors was removed by OPTN/
UNOS in 2009.
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In general, OPTN/UNOS policy limits recommendations for lab‐
oratory testing to assays approved by the FDA for purpose of donor 
screening. Currently, 3 assays are FDA‐approved for screening of po‐
tential organ donors in the United States and one assay is approved 
for confirmatory testing.40 The characteristics of each assay are de‐
scribed in Table 1. A major limitation to donor screening is the inabil‐
ity of any licensed screening test to distinguish HTLV‐1 from HTLV‐2 
and the practical challenges to completing a confirmatory test prior 
to organ donation. Nonetheless, recent reports—including one from 
the US—describe additional cases of proven or probable donor‐de‐
rived HTLV‐1 with a high incidence of HAM/TSP in HTLV‐1‐negative 
recipients of HTLV‐1‐positive donors.25‐31 The highest risk situation 
appears to be seronegative recipients of seropositive donors.31 
Further, given the impact of globalization and increasing migration of 
individuals from around the world, there are geographic differences 
in the seroprevalence of HTLV‐1 within the US.9 Targeted screening 
of deceased donors at increased risk for HTLV‐1 must be balanced 
against the poor specificity of available screening tests and the risk 
of discarding uninfected organs. Several of the recent reports have 
highlighted transmission and HTLV‐1‐associated disease from living 
donors.26,28,30 In this circumstance, additional time is available to 
conduct confirmatory testing and avoid unnecessary organ wastage.
6.2 | Follow‐up of recipients at risk for donor‐
derived HTLV‐1
The optimal management and follow‐up of recipients receiving or‐
gans from donors proven or suspected to have HTLV‐1 is unknown. 
In cases of screen‐positive donors, every effort should be made to 
perform confirmatory tests on stored donor samples to determine if 
the donor is actually HTLV‐1‐infected. Recipients of HTLV‐2‐positive 
donors or those with negative confirmatory assays do not require 
specific follow‐up. If the donor is proven to have HTLV‐1 or con‐
firmatory tests cannot be done or are indeterminate, periodic testing 
for HTLV‐1 using both serological (may have low sensitivity in immu‐
nosuppressed patients) and nucleic acid‐based testing on the recipi‐
ent is indicated. Testing quarterly for 1 year and then biannually for 
1 year would be a reasonable approach. While therapeutic options 
are uncertain, recipients would benefit from knowing their HTLV‐1 
status to prevent secondary (sexual or breastfeeding) transmission 
(see below). Further, HTLV‐1 viral loads are higher in patients with 
neurological disease than in asymptomatic carriers,41,42 and patients 
with donor‐derived infection might benefit from viral load guided 
modulation in their immunosuppression. While HTLV‐1 viral loads 
appear to be maintained by cell division rather than production of 
new virus and tend to remain stable, this may not be true in immu‐
nosuppressed patients.
Standardized clinical monitoring for complications of HTLV‐1 
infection is not well established. ATL may present with any of a 
number of clinical features, including generalized adenopathy, cuta‐
neous lesions, hypercalcemia, bony lesions, and/or isolated periph‐
eral blood abnormalities/leukemia. HAM/TSP is equally variable in 
clinical manifestation, and may present with stiff gait, spasticity and 
lower extremity weakness, back pain, urinary incontinence, impo‐
tence, paresthesias, decreased sensation (particularly for posterior 
column modalities such as vibratory sense), and upper motor neuron 
signs.43
6.3 | Risk to staff
Human T‐cell lymphotrophic virus 1 is spread by cell‐associated virus, 
rather than by cell‐free virus and body fluids, and is transmitted by 
blood products, sexual activity, and breastfeeding. As with other 
blood‐borne pathogens, the greatest risk for healthcare workers car‐
ing for an HTLV‐1‐infected patient is accidental inoculation via con‐
taminated sharps. While transmission of both HTLV‐1 and HTLV‐2 in 
the occupational setting have been reported,44,45 in another report 
no seroconversions occurred among 34 healthcare workers exposed 
Assay Comments
Abbott HTLV‐I/II • Practical for OPO use
• No longer available in the United States
• Does not distinguish between HTLV‐1 and HTLV‐2
Abbott Prism HTLV‐I/
II
• Designed for large scale use (blood produce donor screening)
• Not practical in most OPO laboratories
• Requires significant investment in expensive equipment and 
reagents
• Does not distinguish between HTLV‐1 and HTLV‐2
Avioq HTLV‐I/II 
Microelisa System
• Approved for HTLV screening
• Recently approved (March 2012) and practicality for OPO use 
unproven
• Does not distinguish between HTLV‐1 and HTLV‐2
MP Diagnostics HTLV 
Blot 2.4
• Approved as a supplemental test to confirm a reactive screening 
test result
• May distinguish HTLV‐1 from HTLV‐2
Abbreviations: HTLV, human T‐cell lymphotrophic virus; OPO, organ procurement organizations
TA B L E  1   FDA‐approved HTLV‐1/2 
screening assays
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by puncture wounds.46 No data exist on appropriate prophylaxis for 
individuals exposed to HTLV. While some have recommended the 
use of antiretroviral agents in settings of severe exposure (eg, zido‐
vudine/lamivudine/raltegravir),38,47,48 the CDC and other US agen‐
cies do not recommend post‐exposure prophylaxis due to the lack 
of available data. As with other blood‐borne pathogens, universal, 
standard precautions and scrupulous sharps safety are considered 
sufficient for the prevention of HTLV acquisition.
6.4 | Risk to others (Secondary transmission)
In the non‐occupational setting, transmission may occur horizon‐
tally (usually through sexual activity, or through sharing of injection 
drug needles) or vertically (mother‐to‐child, almost entirely through 
breastfeeding). These can be issues for a recipient who received an 
HTLV‐1‐infected or possibly infected organ, or for an HTLV‐unin‐
fected SOT recipient who may be entering a sexual relationship with 
an HTLV‐infected partner. The effects of immunosuppression on the 
risk of acquisition of HTLV are not understood, though at least one 
animal model suggests that cyclosporine at the time of HTLV‐1 in‐
fection increased the viral set point and might result in increased 
risk of the development of HTLV‐1‐associated disease.49 For the 
HTLV‐1‐infected SOT recipient, a few general comments apply with 
respect to transmission. Sexual transmission of HTLV‐1 can be pre‐
vented effectively with condom use and other safer sex practices 
(as recommended for prevention of HIV transmission). Transmission 
by (injection) needles can be minimized by employment of sterile 
needles with each use and by avoidance of sharing of needles and 
other potentially contaminated equipment. Vertical transmission 
can be decreased by avoidance of breastfeeding (particularly in the 
US and other resource‐rich settings, where breast milk alternatives 
are available).
Recommendations (see Table 2)
• While the impact of immunosuppression on the natural history of 
HTLV‐1 is not fully understood, persons seropositive for HTLV‐1 
can be considered for transplantation. Given that these recipients 
may face a higher (but difficult to quantify) risk of serious disease 
(ATL and HAM/TSP), information regarding this risk should be 
provided to HTLV‐1‐positive potential recipients as part of the in‐
formed consent process (strong, low).
• In low seroprevalence areas (like North America), only in extreme 
circumstances should confirmed HTLV‐1 seropositive donors be 
used. As routine HTLV‐1 screening of deceased donors is no lon‐
ger performed by most OPOs, the most likely scenario would be a 
living donor in whom confirmatory testing could be performed or 
a high‐risk deceased donor in whom screening and confirmatory 
testing is performed (strong, moderate).
• Due to the low seroprevalence of HTLV‐1 in the United States and 
the poor positive predictive value of screening HTLV‐1/2 assays 
in this population, routine screening of all deceased donors is not 
recommended (strong, moderate).
• Individual OPOs with higher prevalence populations (eg, a high 
proportion of immigrants from endemic countries) could consider 
targeted or universal screening. However, even in these higher risk 
donors, most screen‐positive donors likely will not have HTLV‐I. 
If access to rapid confirmatory testing is available, this would de‐
crease the number of uninfected organs discarded (weak, low).
• Living donors with epidemiological risk factors for HTLV‐1 should 
be screened for HTLV‐1 as in this situation adequate time to per‐
form confirmatory testing is available (strong, low).
• Recipients of confirmed or suspected HTLV‐1‐infected organs 
should undergo periodic monitoring using both serological 
and nucleic acid‐based testing (quarterly for 1 year then every 
6 months for 1 year) (strong, low).
• Since the time to development of HTLV‐1‐associated complica‐
tions in immunosuppressed patients post‐transplantation is un‐
known, follow‐up of seropositive SOT recipients should include 
regular clinical monitoring for complications of infection, includ‐
ing ATL and HAM/TSP (focusing on the skin, lymph nodes, he‐
matologic system, and neurological system), in conjunction with 
routine post‐SOT follow‐up care (strong, low).
• Solid‐organ transplantation recipients who are HTLV‐infected (or 
received potentially infected organs) should be counseled about 
risks of transmission to others, including how to minimize those 
risks (strong, low).
• Solid‐organ transplantation recipients who are at risk for acquir‐
ing HTLV‐1 should be counseled on modes of transmission and 
how to minimize the risk of acquisition. In general, these recom‐
mendations follow those for other viruses such as HIV or hepatitis 
C (strong, low).
• Standard, universal precautions should be employed when pro‐
viding care to patients with HTLV‐1 infection (strong, low).
• There is insufficient evidence to recommend occupational post‐
exposure prophylaxis for those who are exposed to HTLV‐1 
(weak, very low).
7  | FUTURE RESE ARCH
A number of important issues regarding HTLV‐1/2 and SOT re‐
cipients remain undefined. Perhaps most importantly, since most 
donors in the US are not screened for HTLV‐1, the transplant com‐
munity should monitor for cases of ATL or HAM in recipients that 
could represent donor‐derived infection. The handful of donor‐de‐
rived cases reported combined with local communities in the US 
with increased prevalence of HTLV‐1, highlights the need for im‐
proved assays that are practical for use in OPOs and can efficiently 
distinguish HTLV‐1 from HTLV‐2 if targeted deceased donor screen‐
ing is to be fully endorsed. We also need to better understand the 
effect of immunosuppression on the natural history of asympto‐
matic HTLV‐1 infection, and additional case series from endemic 
regions are needed. Finally, further studies are needed to better 
define the role of antiretrovirals as post‐exposure prophylaxis.
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TA B L E  2   Summary of recommendations
Recommendation Level of Evidence Comment
Diagnosis Whenever possible, screen‐positive results 
should be confirmed with western blot, line im‐
munoassay, or PCR
(Strong, low) Most screen‐positive donors or recipients will 
not have HTLV‐1.
Treatment No specific proven treatment of asymptomatic 
HTLV‐1 infection is available
(Weak, very low) Proposed treatments include corticosteroids, 
alpha interferon, anti‐CD25 monoclonal anti‐
body, cyclosporine, and valproic acid.
Prevention In low seroprevalence areas, confirmed HTLV‐1‐
positive donors should only be used in extreme 
circumstances.
(Strong, moderate) While routine screening is no longer required, 
in some circumstances (eg, living donors) con‐
firmed serostatus may be available.
Donor screening Routine screening of all deceased donors for 
HTLV‐1 is not recommended
(Strong, moderate) In low seroprevalence areas, most screen‐posi‐
tive donors do not have HTLV‐1 resulting in 
significant wastage of uninfected organs.
Individual OPO’s with higher prevalence popula‐
tions (eg, immigrants from high prevalence 
countries) could consider targeted screening.
(Weak, low) While a positive screening test in a higher risk 
donor is more likely to represent a true‐positive, 
even in this circumstance if a timely confirma‐
tory test cannot be performed most screen‐
positive donors will likely not have HTLV‐1.
Living donors with epidemiological risk factors 
(eg, previous residence in endemic area) should 
be screened as time frame allows for perfor‐
mance of confirmatory testing.
(Strong, low) Reports of donor‐derived HTLV‐1 disease justify 
testing in higher epidemiological risk donors 
when adequate time for confirmatory testing is 
available.
Recipient issues Periodic testing (quarterly for 1 y and then 
biannually for 1 y) with both PCR and serology 
should be performed on recipients of proven or 
suspected HTLV‐1‐infected donors.
(Strong, low) While no proven intervention is available, 
recipients with the potential for donor‐derived 
HTLV‐1 should be made aware of the risk of 
secondary transmission (sexual or breastfeed‐
ing) and investigational treatments/prophylaxis 
could be considered.
HTLV‐1 seropositive individuals should not be 
excluded from transplantation, but informed 
consent should be obtained.
(Strong, low) Reports demonstrate good outcomes without 
the development of HTLV‐1 disease after 
transplantation. Immunosuppression may speed 
the development of HTLV‐1 disease; HTLV‐1 
related deaths have been reported after organ 
transplantation.
Follow‐up of HTLV‐1‐positive SOT recipients 
should include regular clinical monitoring for 
complications of infection, including ATL and 
HAM/TSP.
(Strong, low) Investigational (HAM/TSP) and standard (ATL) 
treatments could be considered.
SOT recipients who are HTLV‐1‐infected (or 
received potentially infected organs) should be 
counseled about risks of transmission to others, 
including how to minimize those risks
(Strong, low) HTLV‐1 can be transmitted through sexual con‐
tact, breastfeeding, or sharing injection needles. 
HTLV‐1 cannot be transmitted through casual 
contact.
SOT recipients who are at risk for acquiring 
HTLV‐1 should be counseled on modes of 
transmission and how to minimize the risk of 
acquisition. In general, these recommendations 
follow those for other viruses such at HIV or 
hepatitis C (Category III).
(Strong, low) This would primarily apply to transplant recipi‐
ents who are sexual partners of HTLV‐1‐in‐
fected individuals.
Infection control Standard, universal precautions should be 
employed when providing care to patients with 
HTLV infection
(Strong, low) In occupational settings, HTLV‐1 transmission is 
similar to other blood‐borne viruses (HIV).
There is insufficient evidence to recommend oc‐
cupational post‐exposure prophylaxis for those 
who are exposed to HTLV‐1
(Weak, very low) The use of antiretrovirals immediately after 
exposure could theoretically prevent the estab‐
lishment of infection, but there is only in vitro 
data to support this.
Abbreviations: ATL, adult T‐cell leukemia; HAM/TSP, HTLV‐associated myelopathy/tropical spastic paraparesis; HIV, human immunodeficiency virus; 
HTLV, human T‐cell lymphotrophic virus; OPO, organ procurement organizations; PCR, polymerase chain reaction; SOT, solid‐organ transplant.
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